Moreover, in a study of 158 cases of nonsmall cell lung cancer, Marsit et al (2004) found 22 (14%) to have promoter methylation of FANCF, and this was also associated with adverse survival (HR=3.1, 95% CI: 1.2–7.9, P not reported). Here, FANCF is linked to lung cancer.